Cart (0 Items)
Your cart is currently empty.
View ProductsStable Isotope Labelled Ipilimumab Biosimilar – Anti-CTLA-4 mAb – Research Grade
| Size | |
|---|---|
| Brand | |
| Product type | |
| Clonality | |
| Expression system | |
| Applications |
| Product name | Stable Isotope Labelled Ipilimumab Biosimilar - Anti-CTLA-4 mAb - Research Grade |
|---|---|
| Source | DrugBank DB06186 |
| Species | Human |
| Expression system | Mammalian cells |
| Molecular weight | 148kDa |
| Purity | >95% |
| Buffer | PBS pH7.5 |
| Delivery condition | Blue ice (+4°C) |
| Delivery Time | 3-5 days if in stock; 5-8 weeks if production needed |
| Storage condition | 4°C for short term; -20°C for long term |
| Brand | ProteoGenix |
| Applications | MS |
| Aliases /Synonyms | Ipilimumab |
| Reference | PX-TA1021-SIL |
| Related Products | PX-P4782 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |
| Isotype | IgG1Kappa |
| Clonality | Monoclonal Antibody |
| Format | Lyophilized |
| Labelling | Arginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99% |
| Isotopic Enrichment | 99% |
| Stability | 1 year |
| Formula | C6572H10126N1734O2080S40 |
Description of Stable Isotope Labelled Ipilimumab Biosimilar - Anti-CTLA-4 mAb - Research Grade
General information about Ipilimumab
Ipilimumab is a monoclonal antibody used in the treatment of melanoma. It is an antibody that inhibits the CTLA-4 checkpoint of T lymphocytes, a checkpoint that certain cancers activate to decrease the efficiency of the lymphocyte. Ipilimumab is a human monoclonal antibody of the IgG1 type directed against the CTLA-4 protein (Cytotoxic T-Lymphocyte Antigen 4). The inhibition of this receptor present on the T lymphocytes results in the activation of the T lymphocyte. This product is for research use only.
Reviews
Il n’y a pas encore d’avis.